CHINESE JOURNAL OF DRUG EVALUATION ›› 2022, Vol. 39 ›› Issue (5): 370-376.

Previous Articles     Next Articles

Research Hotspot and Frontier Analysis of Children′s Medication Safety Research in China

  

  1. 1.School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;  2.Institute for Excellence in Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;  3.National Institute of Chinese Medicine Development and Strategy, Beijing University of Chinese Medicine, Beijing 100029,China
  • Received:2022-10-17 Revised:2022-10-10 Online:2022-10-28 Published:2022-10-28

Abstract: Objective:To conduct bibliometric visual analysis of the research of children medication safety in China, and provide a reference for improving the drug safety of children. Methods: Literatures were retrieved from CNKI, VIP, and Wanfang database. Bibliometrics method and CiteSpace were used to analysis on the annual quantity of publications, authors, and institutions. Keywords were analyzed by co-occurrence analysis, cluster analysis and emergence analysis. Results: A total of 4189 literatures were included, and the quantity of literatures was on the rise. The institution with the highest number of publications was Capital Medical University affiliated Beijing Children′s Hospital. There were many projects supported by national scientific research funds (National Natural Science Foundation of China, National Science and Technology Major Projects). Research hotspots and frontier words mainly include antibacterial drugs, antiepileptic drugs, clinical pharmacists, Chinese patent medicines, and prescription review. Conclusion: The issue safety of medication for children in China has attracted increasing attention. Scholars from various institutions should strengthen communication and cooperation to further improve the quality of research. It was suggested to strengthen the regulation and management of the use of antibiotics and antiepileptic drugs, attach importance to the development of pharmaceutical care for clinical pharmacists, improve the standardization of the clinical use of Chinese patent medicine, and optimize the prescription comment process in future studies on the safety of pediatric medication, so as to promote the high-quality development of pediatric medication in China.

Key words: font-size:medium, ">Medicine for Children; Safety; Bibliometrics; Knowledge graph

CLC Number: 

[an error occurred while processing this directive]